Nonhuman Primate Reagent Resource

非人类灵长类动物试剂资源

• 批准号: 10304631
• 负责人: Kathleen Engelman
• 金额: $ 177.4万
• 依托单位: UNIV OF MASSACHUSETTS MED SCH WORCESTER
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-29 至 2026-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10304631
• 关键词: Animal Model; Animals; Antibodies; Biological; Biological Markers; Biological Response Modifier Therapy; Biological Testing; Cells; Communicable Diseases; Communities; Community Outreach; Data; Databases; Development; Development Plans; Discipline; Disease; Disease model; Engineering; Five-Year Plans; Formulation; Future; Goals; Human; Immune; Immunologics; Immunomodulators; Infrastructure; Methodology; Modeling; Monkeys; Monoclonal Antibodies; Names; Natural Killer Cells; Organ Transplantation; Pathogenesis; Peptide Hydrolases; Population; Production; Quality Control; Reagent; Recombinant Antibody; Recombinants; Records; Research; Research Personnel; Resources; Role; Scientific Advances and Accomplishments; Services; Source; Translational Research; Vaccines; antibody detection; design; expression vector; human disease; human model; immunoregulation; in vivo; in-vitro diagnostics; large scale production; next generation; nonhuman primate; novel; novel therapeutics; operation; outreach; pre-clinical; programs; response; tool; web site

Summary The Nonhuman Primate Reagent Resource (NHPRR) has 21 years of continuous operation providing specialized reagents to enable and enhance research with nonhuman primate (NHP) models of human disease. This application describes our next five-year plan to develop and distribute these essential NHP- tailored reagents. NHPs serve a crucial role in translational research, providing animal models for exploring the pathogenesis of infectious and noninfectious diseases, and for testing biological therapies and vaccines. Antibodies and biological reagents that target specific immune cells and biomarkers can be essential tools in determining disease mechanisms. Additionally, immunomodulators that can be studied in vivo serve as proof-of-concept for new therapies. While these crucial research tools are available for small animal and human studies, substantial gaps exist for validated NHP research reagents. To overcome this scarcity, for the past 21 years, the NHPRR has fulfilled critical needs within the scientific community by developing, manufacturing and distributing NHP-specific reagents for in vitro diagnostics and for in vivo use. Utilization of this resource has grown dramatically since this program’s inception. During the last five years (2015-2019), we fulfilled 2,821 reagent requests for 320 investigators and distributed ~2,500 grams of recombinant antibodies for administration to NHPs. By continuously availing ourselves of future scientific advances and technological improvements in antibody development, engineering, expression and vectoring, we will keep supporting the scientific community utilizing NHP models across all scientific disciplines.

概括 非人类灵长类动物试剂资源 (NHPRR) 已连续运行 21 年，提供 专用试剂可促进和加强人类非人灵长类 (NHP) 模型的研究 疾病。该应用程序描述了我们的下一个五年计划，以开发和分发这些基本的 NHP- 定制试剂。 NHP 在转化研究中发挥着至关重要的作用，为探索 传染性和非传染性疾病的发病机制，以及测试生物疗法和疫苗。 针对特定免疫细胞和生物标志物的抗体和生物试剂可能至关重要 确定疾病机制的工具。此外，可以在体内研究的免疫调节剂 作为新疗法的概念验证。虽然这些重要的研究工具可供小型企业使用 动物和人类研究中，经验证的 NHP 研究试剂存在巨大差距。克服 由于这种稀缺性，在过去 21 年里，NHPRR 满足了科学界的关键需求 通过开发、制造和分销用于体外诊断和体内诊断的 NHP 特异性试剂 体内使用。自该计划启动以来，该资源的利用率急剧增长。期间 过去五年（2015-2019），我们满足了 320 名研究人员的 2,821 份试剂请求，并分发了 约 2,500 克重组抗体用于 NHP 给药。 通过不断利用未来的科学进步和技术改进 抗体开发、工程、表达和载体，我们将继续支持科学 社区在所有科学学科中利用 NHP 模型。